A

ANI Pharmaceuticals
D

ANIP

54.170
USD
0.75
(1.40%)
Market Closed
Volume
5,687
EPS
4
Div Yield
-
P/E
-115
Market Cap
1,138,532,872
OverviewSignalsIdeasNews
Related Instruments
    C
    CAH
    0.100
    (0.08%)
    118.360 USD
    H
    HSIC
    0.230
    (0.33%)
    70.020 USD
    I
    ICLR
    2.330
    (1.12%)
    210.010 USD
    IDXX
    IDXX
    0.49
    (0.12%)
    412.94 USD
    L
    LH
    -0.760
    (-0.33%)
    227.900 USD
    P
    PAHC
    -0.075
    (-0.35%)
    21.640 USD
    P
    PETQ
    0.000
    (0.00%)
    30.990 USD
    P
    PRGO
    -0.120
    (-0.47%)
    25.650 USD
    ZBH
    ZBH
    -0.240
    (-0.22%)
    106.810 USD
    ZTS
    ZTS
    -0.500
    (-0.30%)
    164.250 USD
    More
News

Title: ANI Pharmaceuticals

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
ANI Pharmaceuticals Inc develops, manufactures, and markets generic prescription pharmaceuticals. It manufactures liquid, powder, and oral solid dose products. Its areas of product development include narcotics, oncolytic, hormones and steroids, and complex formulations involving extended release and combination products. Some of its generic products include Erythromycin ethyl succinate, Esterified Estrogen with Methyltestosterone (EEMT), Etodolac Fenofibrate, Fluvoxamine, Hydrocortisone Enema and Vancomycin. Its geographical segments are the United States and Canada, of which the majority of its revenue comes from the United States.